1984-2004: two decades of major regulatory change in the EU
This article was originally published in Clinica
Twenty years ago this month, Clinica's longest-serving journalist, Amanda Maxwell, started work on her first story for what has become the world's leading medical devices and diagnostics industry news publication. Here, she reflects on the enormous regulatory changes in the EU over that time and how they have impacted every corner of the world, and looks forward to Clinica, now under new ownership, continuing to deliver news services that meet readers' demands in this new era of information
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.